Episode # 305 • 02 Jun 2026
Immune Therapy Innovations for BCG Unresponsive Cancer
Ready to move beyond “one-size-fits-all” for BCG-unresponsive NMIBC? In this episode of BackTable Urology, Dr. Ruchika Talwar hosts Dr. Sam Chang to discuss the evolving treatment landscape for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). They explore why BCG may fail, the science and clinical rationale behind new immunotherapies and gene therapies, practical approaches to patient selection, treatment sequencing, and surveillance, and the value of emerging biomarkers, empowering urologists to make more informed, personalized decisions in complex cases of NMIBC.
This podcast is supported by
Timestamps
00:00 - Introduction
03:48 - BCG: How it Works and Why it Fails
11:13 - Pembrolizumab Role and Limits
14:38 - Nadofaragene firadenovec
16:34 - Cretostimogene grenadenorepvec
18:39 - BCG + Anktiva Rationale
29:50 - Explaining Options to Patients
33:05 - Post Treatment Surveillance
37:32 - Future of Biomarkers and AI
42:05 - Key Takeaways
Resources
- N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review
- Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer
- IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
You may also like
More about this episode
This podcast is for informational purposes only. The views and opinions expressed in this podcast are solely those of the moderator and individual guest.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.